Drug Type Autologous CAR-T |
Synonyms Autologous CD19/CD20CART cells |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 1 | China | 19 Apr 2019 | |
CD19 Positive Lymphoma | Phase 1 | China | 19 Apr 2019 | |
CD20 positive Hematologic Neoplasms | Phase 1 | China | 19 Apr 2019 | |
Chronic Lymphocytic Leukemia | Phase 1 | China | 19 Apr 2019 | |
Non-Hodgkin Lymphoma | Phase 1 | China | 19 Apr 2019 | |
Recurrent Hematologic Malignancy | Phase 1 | China | 19 Apr 2019 | |
Refractory Hematologic Malignancy | Phase 1 | China | 19 Apr 2019 |